New drug trial targets Hard-to-Treat prostate cancer
NCT ID NCT07493512
First seen Apr 03, 2026 · Last updated May 26, 2026 · Updated 7 times
Summary
This early-phase study tests a new drug called xaluritamig in 40 adults with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The main goal is to check the drug's safety and side effects. Researchers will also measure how the drug moves through the body. Participants must have cancer that has spread and is getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Next Oncology - Dallas
RECRUITINGIrving, Texas, 75039, United States
Conditions
Explore the condition pages connected to this study.